Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Learning About Sickle Cell Disease
source: The National Human Genome Research Institute
year: 2020
summary/abstract:Sickle cell disease is the most common inherited blood disorder in the United States. Approximately 100,000 Americans have the disease.
In the United States, sickle cell disease is most prevalent among African Americans. About one in 12 African Americans and about one in 100 Hispanic Americans carry the sickle cell trait, which means they are carriers of the disease.
Sickle cell disease is caused by a mutation in the hemoglobin-Beta gene found on chromosome 11. Hemoglobin transports oxygen from the lungs to other parts of the body. Red blood cells with normal hemoglobin (hemoglobin-A) are smooth and round and glide through blood vessels.
In people with sickle cell disease, abnormal hemoglobin molecules – hemoglobin S – stick to one another and form long, rod-like structures. These structures cause red blood cells to become stiff, assuming a sickle shape. Their shape causes these red blood cells to pile up, causing blockages and damaging vital organs and tissue.
read moreRelated Content
-
Fighting Painful Misconceptions About Sickle Cell Disease in the ERWhen sickle cell patients arrive at emer...
-
23andMe, Morehouse School of Medicine and the Sickle Cell Foundation of Georgia Inc. launches the Sickle Cell Carrie...Atlanta, GA: April 11, 2023 — 23andMe ...
-
Immunoglobulin G Responses Against Falciparum Malaria Specific Antigens are Higher in Children with Homozygous Sickl...Background: High Immunoglobulin G (IgG)...
-
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
Step toward gene therapy for sickle cell diseaseA team of researchers at the Stanford Un...
-
Today’s Faces of Sickle Cell Disease: Deidra Flowers-WilliamsAt six months of age, Deidra Flowers-Wil...
-
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell TrialSancilio Pharmaceuticals says its invest...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.